Business
RAMSAY SANTE : Unaudited interim results at end March 2026
PRESS RELEASE Paris, 7th May 2026 Unaudited interim results at end March 2026 Solid fundamentals driving revenue growth, with strengthened efficiency gains lifting operational profitabilityPublic funding to mitigate cost inflation still a challenge 9M Group Revenue up 3.1% to €4.0bn (+1.9% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation, favourable currency effects, and the first quarter of contribu
About this update from Ramsay Generale De Sante Sa
[{"type":"image","alt":"RAMSAY SANTE","displaySize":"","headline":null,"caption":"RAMSAY SANTE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":288,"url":"https://media.zenfs.com/en/globenewswire.com/959bad3a6a10a6a66985b8a318e1818f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H9PM9FpeX.ZeQNPJNzn8pQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQwMw--/https://media.zenfs.com/en/globenewswire.com/959bad3a6a10a6a66985b8a318e1818f","width":300,"height":288},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/H9PM9FpeX.ZeQNPJNzn8pQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQwMw--/https://media.zenfs.com/en/globenewswire.com/959bad3a6a10a6a66985b8a318e1818f","width":300,"height":288}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"Paris, 7th May 2026","length":19,"tagName":"p"},{"type":"text","content":"Unaudited interim results at end March 2026","length":43,"tagName":"p"},{"type":"text","content":"Solid fundamentals driving revenue growth, with strengthened efficiency gains lifting operational profitabilityPublic funding to mitigate cost inflation still a challenge","length":171,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"9M Group Revenue up 3.1% to €4.0bn (+1.9% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation, favourable currency effects, and the first quarter of contribution from the new St Göran contract.","length":287,"tagName":"p"}]},{"val":[{"type":"text","content":"9M Group EBITDA up 4.4% at €460m (11.6% margin), with efficiency, performance improvement and sustained operating cost control offsetting (i) the anticipated €20m shortfall in French revenue guarantee, (ii) the impact of a strike by French medical practitioners in January 2026 protesting against government measures, and (iii) insufficient public tariff funding versus cost inflation.","length":385,"tagName":"p"}]},{"val":[{"type":"text","content":"Q3 Group EBITDA up +12,3% or +19m€ at €176m (€156m in Q3 25) notably reflecting increasing productivity efforts and cost control across all geographies and including a 9m€ positive effect from the cancellation of the CICE coefficient not applied to January and February last year.","length":280,"tagName":"p"}]},{"val":[{"type":"text",...